# Simu K. Thomas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/simu-k-thomas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,892 |
| Field | Dementia and Cognitive Impairment Research |
| h-index | 25 |
| i10-index | 34 |
| Last Known Institution | Alexion Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5112537616 |
| Works | 76 |

## Researcher papers

- [Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs](https://scholariq.org/papers/treatment-interruptions-and-non-adherence-with-imatinib-and-associated/)
- [Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review](https://scholariq.org/papers/consequences-and-costs-of-noncompliance-with-iron-chelation-therapy-in-patients/)
- [Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease](https://scholariq.org/papers/caregiver-preference-for-rivastigmine-patch-relative-to-capsules-for-treatment/)
- [Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase Inhibitors](https://scholariq.org/papers/risk-of-cancer-treatment-associated-bone-loss-and-fractures-among-women-with/)
- [Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial](https://scholariq.org/papers/cost-effectiveness-of-ranibizumab-in-treatment-of-diabetic-macular-oedema-dme/)
- [Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients](https://scholariq.org/papers/cost-effectiveness-of-once-daily-oral-chelation-therapy-with-deferasirox-versus/)
- [Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer??s Disease and Other Dementias](https://scholariq.org/papers/functional-impairment-healthcare-costs-and-the-prevalence-of/)
- [Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease](https://scholariq.org/papers/caregiver-preference-for-rivastigmine-patches-versus-capsules-for-the-treatment/)
- [A cost-utility analysis of interferon beta for multiple sclerosis.](https://scholariq.org/papers/a-cost-utility-analysis-of-interferon-beta-for-multiple-sclerosis/)
- [Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder](https://scholariq.org/papers/effect-of-comorbidities-on-medical-care-use-and-cost-among-refractory-patients/)
- [Alzheimer’s disease treatment: Assessing caregiver preferences for mode of treatment delivery](https://scholariq.org/papers/alzheimer-s-disease-treatment-assessing-caregiver-preferences-for-mode-of/)

## Researcher topics

- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Iron Metabolism and Disorders](https://scholariq.org/topics/iron-metabolism-and-disorders/)

## Researcher university

- [Alexion Pharmaceuticals (United States)](https://scholariq.org/institutions/alexion-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.